Thus, further investigation of VIP and PACAP immunomodulatory function on CMT mouse models could potentially develop VIP and PACAP as novel molecules for the treatment of peripheral neuropathies. This evidence concerns the gene VIP and Charcot-Marie-Tooth disease.